Imperial Innovations Limited

Oregon Health & Science University

Ip2ipo Innovations Limited

Imperial College Innovations Limited

Stephen Robert Bloom

Caroline Jane Small

Mohammad Ali Ghatei

Roger D Cone

Michael Alexander Cowley

Andrew A Butler

Rachel Louise Batterham

Malcolm J Low

Catherine Louise Dakin

Stanley Moore

Malcolm James Duncan Low

Mohammad Ali Ghatel

Michael Cowley

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

Analogues of PYY

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention has been shown, in animal models, to result in increased weight loss.

Glucagon-like peptides

Peptide hormone analogs of the formula X-V are provided herein, wherein X is a glucagon analog or a GLP1 analog, and V is a C-terminal extension amino acid sequence comprising at least four amino acid residues, at least three of said residues being His. Also provided herein are pharmaceutical compositions comprising said analogs, and methods of using said analogs for the treatment of conditions such as obesity and diabetes.

Peptides hormone analogues derivable from preproglucagon

Peptide containing sequence from both the GLP-1 peptide and glucagon peptide, compositions comprising said peptides and methods of using said peptides for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as obesity or diabetes, are provided.

Compounds and their effects on feeding behaviour

Peptide analogs of glucagon and peptide analogs of GLP1 are provided herein. Also provided herein are pharmaceutical compositions comprising the analogs, and methods of using the analogs for the treatment and/or prevention of conditions such as obesity and diabetes.

Peptide analogues of glucagon and GLP1

Peptide analogues of PYY, compositions comprising said analogues and methods of using said analogues for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for a reduction in appetite, reduction in food intake or reduction of calorie intake in a subject.

Peptide tyrosine tyrosine analogues

Peptide analogs of peptide YY (PYY), compositions comprising them, and methods of using those analogs or compositions for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for reduction in appetite, reduction in food intake or reduction of calorie intake in a subject, are provided herein.

The invention provides a compound of formula (I): X-PYY* (3-36) (I) wherein X is selected from H, PYY(ie Tyr Pro) and D-Allo-Ue; PYY*(3-36) representing PYY (3-36) in which one or more residues is replaced by an acylated lysine group, the acyl group being selected from: CO&#x2014;Calkyl, CO&#x2014;Calkenyl, CO&#x2014;Caryl and CO&#x2014;Car-Calkyl; a variant or derivative thereof; or a salt or solvate thereof. The compounds are effective in inducing satiety and suppressing appetite and they are thus useful in treating various diseases, including obesity.

Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.

Modification of feeding behavior

The present invention relates to compounds of formula (I); variants or derivatives thereof, or salts or solvates thereof. The present invention also relates to the use of such compounds to control appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the treatment of obesity. 

Modified PYY (3-36) peptides and their effects on feeding behavior

The invention features peptides for the treatment or prevention of obesity, diabetes or co-morbidities of obesity; for reduction of appetite, food intake, calorie intake, body weight, or body weight gain; and for increase of energy expenditure in a subject.

Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject.

Modification of feeding behavior using PYY and GLP-1

The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure.

Modification of feeding behaviour

Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.

Growing community of inventors

London, United Kingdom

Stephen Robert Bloom